LABD vs XBIX: which held to its multiple?
Over three months against its own daily promise, LABD finished 3.0 points over and XBIX 2.5 points short. Direxion Daily S&P Biotech Bear 3X ETF and Corgi U.S. Biotech 2x Daily ETF.
LABD returned −10.6% while −3 times XBI's move would have been −2.2%
XBIX returned −3.1% while 2 times XBI's move would have been +1.4%
LABD among the 125 inverse ETFs over three months
XBIX among the 470 leveraged ETFs, long, over three months
A percentile among the 125 inverse ETFs over three months. XBIX is a percentile among the 470 leveraged ETFs, long, over three months, a different set, so the two marks are not on one scale. It is a position in a set, not a rating, and neither end of it is a recommendation. All leveraged ETFs ranked by it → How it is computed →
Performance, window by window
| Total return | Multiple would give | Difference | ||||
|---|---|---|---|---|---|---|
| Window | LABD | XBIX | LABD | XBIX | LABD | XBIX |
| 1 month | +7.0% | −6.8% | +8.9% | −5.9% | −1.9 pts | −0.9 pts |
| 3 months | −10.6% | −3.1% | −2.2% | +1.4% | −8.5 pts | −4.6 pts |
| 6 months | −55.1% | not published | −68.3% | not published | +13.2 pts | not published |
| 1 year | −82.0% | not published | −174.1% | not published | +92.0 pts | not published |
| 3 years | −96.2% | not published | not meaningful | not published | not meaningful | not published |
| Since launch LABD May 2015 · XBIX Jun 2026 | −100.0% | +39.1% | not meaningful | +43.1% | not meaningful | −4.1 pts |
LABD and XBIX over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ. Open the live comparison on ETFIQ →
On the same fields
LABD and XBIX on the same fields, as of Sep 30, 2026. Source: ETFIQ.
LABD in plain words
Three months to Sep 30, 2026: LABD returned −10.6% where its own daily promise gave −13.6%, 3.0 points over. Read the multiple against the whole window instead and −3 times XBI's 0.7% implies −2.2%, which makes LABD look 8.5 points short. 11.5 of that is daily compounding, which happens to any −3 times fund over the same path, and the rest is the fund. LABD aims to return -3 times XBI's move each day, then resets. Over one day it does that. Over longer, the daily results compound, so the total is not -3 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more. XBI moved at 29% annualized over that window. That is what decides how far the two figures separate: the same fund on a calm underlying and a violent one is a different product.
XBIX in plain words
Three months to Sep 30, 2026: XBIX returned −3.1% where its own daily promise gave −0.6%, 2.5 points short. Read the multiple against the whole window instead and 2 times XBI's 0.7% implies +1.4%, which makes XBIX look 4.6 points short. 2.1 of that is daily compounding, which happens to any 2 times fund over the same path, and the rest is the fund. XBIX aims to return +2 times XBI's move each day, then resets. Over longer, the daily results compound, so the total is not +2 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more.
Questions people ask
- Which came closer to its stated multiple, LABD or XBIX?
- Over the window to Sep 30, 2026, LABD finished 8.5 points from what its multiple implies and XBIX finished 4.6 points from its own, so XBIX came closer. Neither figure predicts the next window: it depends on how much the underlying moves about.
- Are LABD and XBIX levered on the same thing?
- Yes. Both are levered on biotech, LABD at -3 times and XBIX at +2 times the daily move.
- Which one decays faster, LABD or XBIX?
- Decay follows how much the underlying moves about. Over this window LABD’s moved at 29% annualized and XBIX’s at 29%, so LABD has the rougher ride and, at the same multiple, loses more to compounding.
- Can I hold LABD or XBIX for a year?
- Both reset every day, so the multiple in the name applies to a single day and the daily results compound. Over a year the total is not the multiple times the year’s move, and in a market that falls and comes back it is reliably less. ETFIQ makes no recommendation either way.
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement. A comparison is not a recommendation.
ETFIQ, LABD against XBIX, data as of Sep 30, 2026. https://etfiq.com/compare/leverage/labd-vs-xbix
Free to use with attribution. Every figure is calculated from a named public source; the method is at etfiq.com/methodology.
Cite this page. ETFIQ, LABD against XBIX, data as of Sep 30, 2026. https://etfiq.com/compare/leverage/labd-vs-xbix Free to use with attribution; the underlying files are at Open data.
Other forms
- Plain
- ETFIQ, LABD against XBIX, data as of Sep 30, 2026. https://etfiq.com/compare/leverage/labd-vs-xbix
- APA
- ETFIQ. (Sep 30, 2026). LABD against XBIX. Retrieved from https://etfiq.com/compare/leverage/labd-vs-xbix
- Markdown
- [LABD against XBIX (ETFIQ, Sep 30, 2026)](https://etfiq.com/compare/leverage/labd-vs-xbix)